Program - Society of Toxicology

More documents

Recommendations

Info

50 th Anniversary Annual Meeting and ToxExpo Program Description (Continued) Wednesday Abstract # Abstract # #2452 2:07 USING NEURAL PROGENITOR CELLS IN HIGH-THROUGHPUT SCREENS FOR DEVELOPMENTAL NEUROTOXICANTS: TRIUMPHS AND TRAGEDIES. T. J. Shafer, M. Culbreth, J. M. Breier and W. R. Mundy. Integrated Systems Toxicology, U.S. EPA, Research Triangle Park, NC. #2453 2:39 TRENDS OF THE IPSC TECHNOLOGY FOR BIOMEDICAL RESEARCH AND CELL THERAPY: POTENTIAL OF PROTEIN- INDUCED IPSCS. K. Kim. McLean Hospital/ Harvard Medical School, Belmont, MA. Sponsor: A. Bowman. #2454 3:11 IN VITRO MODELS OF ANGELMAN AND PRADER-WILLI SYNDROME VIA INDUCED PLURIPOTENT STEM CELL TECHNOLOGY. M. Lalande. Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT. #2455 3:43 PATIENT-DERIVED STEM CELLS AS A TRANSLATIONAL MODEL FOR NEUROTOXICOLOGICAL RISK. A. B. Bowman. Neurology, Vanderbilt University, Nashville, TN. Wednesday Afternoon, March 9 1:30 PM to 4:15 PM Room 145 Toxicity Testing: State of Science and Strategies to Improve Public Health Symposium Session: The Use of Epidemiological Data and PBPK Modeling in a Risk Assessment: Manganese As a Case Study Chairperson(s): Harvey J. Clewell, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, and Daniel Krewski, University of Ottawa, Ottawa, Ontario, Canada. Sponsor: Metals Specialty Section Endorsed by: Biological Modeling Specialty Section Neurotoxicology Specialty Section Risk Assessment Specialty Section Manganese (Mn) is an essential element that is neurotoxic at high exposures. In recent years there has been increasing use of PBPK modeling in quantitative risk assessments to support animal-to-human extrapolation when human risk estimates are based on animal studies. However, any risk assessment for the neurological effects of Mn would likely be based on epidemiological data from occupational exposures to inhaled Mn in dust. Nevertheless, the risk assessment for manganese (Mn) provides an opportunity to apply PBPK modeling in a different aspect of quantitative risk assessment: replacing default uncertainty factors with chemical-specific adjustment factors. The critical issues in a Mn risk assessment based on occupational epidemiology data are the nature and extent of the uncertainty factors that should be applied to account for uncertainties regarding interindividual variability, susceptible sub-populations, duration of exposure, and different forms of Mn. We will describe the epidemiological evidence for the neurotoxic effects of Mn and explore the use of PBPK models for Mn in adult and perinatal animals and humans to predict the effect of key sources of uncertainty on the target tissue Mn dose, elucidate the dose-dependent mode of action for the neurological effects of Mn, and quantify the impact of human variability, life-stage, and other uncertainties on risks estimated from occupational epidemiology studies. #2456 1:30 THE USE OF EPIDEMIOLOGICAL DATA AND PBPK MODELING IN A RISK ASSESSMENT: MANGANESE AS A CASE STUDY. H. J. Clewell 1 , M. Andersen 1 , V. Tait 2 , H. Roels 3 and W. Boyes 4 . 1 The Hamner Institutes for Health Sciences, Research Triangle Park, NC, 2 University of Ottawa, Ottawa, ON, Canada, 3 Université Catholique de Louvain, Brussels, Belgium and 4 U.S. EPA, Research Triangle Park, NC. 1:30 INTRODUCTION. Harvey Clewell #2457 1:35 COLLECTION OF CHEMICAL- SPECIFIC TOXICOLOGICAL AND PHARMACOKINETIC DATA TO IMPROVE RISK ASSESSMENTS BASED ON EPIDEMIOLOGY: EXAMPLE OF MN. W. K. Boyes. U.S. EPA, Research Triangle Park, NC. #2458 2:07 BIOMARKERS OF EXPOSURE TO MANGANESE AND PROSPECTIVE STUDIES OF ITS NEUROTOXIC EFFECTS IN OCCUPATIONAL COHORTS. H. A. Roels. Louvain Centre of Toxicology and Applied Pharmacology, Université catholique de Louvain, Brussels, Belgium. Sponsor: H. Clewell. #2459 2:39 THE USE OF PBPK MODELS FOR MONKEY AND HUMAN TO INVESTIGATE THE DOSE- RESPONSE FOR THE NEUROLOGICAL EFFECTS OF MN. H. J. Clewell 1 , J. D. Schroeter 1 , M. Yoon 1 , A. Nong 1 , M. D. Taylor 2 and M. E. Andersen 1 . 1 The Hamner Institutes for Health Sciences, Research Triangle Park, NC and 2 Afton Chemical, Richmond, VA. #2460 3:11 APPLICATION OF PBPK MODELING TO EVALUATE SAFE EXPOSURES TO A TOXIC BUT ESSENTIAL METAL. M. E. Andersen. Computational Biology, The Hamner Institutes for Health Sciences, Research Triangle Park, NC. #2461 3:43 HAZARD ASSESSMENT FOR THE ESSENTIAL ELEMENT MANGANESE BASED ON TOXICOLOGICAL, EPIDEMIOLOGICAL, AND MECHANISTIC DATA: SUSCEPTIBLE SUB-POPULATIONS AND INTER-INDIVIDUAL VARIABILITY. V. Tait 1,2 , F. Salehi 2 , M. Croteau 2 , N. Karyakina 1,2 , N. Shilnikova 2 , A. Ngom 2 and D. Krewski 2,1 . 1 Risk Sciences International Inc., Ottawa, ON, Canada and 2 University of Ottawa, Ottawa, ON, Canada. Sponsor: M. Andersen. 332 Education-Career Development Sessions Exhibitor Hosted Sessions Featured Sessions Historical Highlights Informational Sessions Platform Sessions
Society of Toxicology 2011 Program Description (Continued) Abstract # Wednesday Afternoon, March 9 1:30 PM to 4:15 PM Room 144 Emerging Global Public Health Issues Workshop Session: Advancing Predictive Ecotoxicology Testing and Environmental Risk Assessment in the 21st Century Chairperson(s): Michelle Embry, ILSI Health and Environmental Sciences Institute, Washington, D.C., and David Volz, University of South Carolina, Columbia, SC. Sponsor: Risk Assessment Specialty Section Endorsed by: Hispanic Organization for Toxicologists Special Interest Group Molecular Biology Specialty Section Following the publication of the National Research Council (NRC) Report on Toxicity Testing in the 21st Century: A Vision and a Strategy increased attention has been given to the development and use of new technologies and methods for toxicity testing. It is hoped that these new approaches will aid in the design of a routine testing strategy that will provide data that are applicable to the broadest possible range of chemicals, endpoints, and lifestages, while also providing greater detail concerning mode of action and dose/concentration-response, and reducing the overall costs, animal use, and time spent on testing. This Tox21 vision has impacted testing approaches for not only human health, but also ecological risk assessment. Therefore it is important to address these current initiatives aimed at advancing regulatory ecotoxity testing strategies. Novel approaches that could be integrated into an intelligent, tiered ecotoxicity testing strategy are under development. Additionally, concepts for utilizing chemical mode of action and/or adverse outcome pathways as a basis for developing 21st century test methods and associated predictive tools, initially developed as part of a SETAC Pellston workshop, have been expanded on several fronts. Advances in the application of QSAR and modeling approaches, cell-based assays, and ‘omics methodologies as well as recent OECD efforts to develop a fish testing framework will be highlighted. Our focus will be to discuss approaches to coordinate the development of new human health and environmental toxicity testing strategies, share key lessons and advances and create effective partnerships between human health and ecotoxicology communities. #2462 1:30 ADVANCING PREDICTIVE ECOTOXICOLOGY TESTING AND ENVIRONMENTAL RISK ASSESSMENT IN THE 21 ST CENTURY. M. Embry 1 and D. Volz 2 . 1 ILSI HESI, Washington, D.C. and 2 University of South Carolina, Columbia, SC. 1:30 INTRODUCTION. Michelle Embry #2463 1:35 ADVERSE OUTCOME PATHWAYS AND SYSTEMS BIOLOGY AS CONCEPTUAL APPROACHES TO SUPPORT DEVELOPMENT OF 21 ST CENTURY TEST METHODS AND EXTRAPOLATION TOOLS. D. L. Villeneuve 1 , M. R. Embry 2 and D. C. Volz 3 . 1 U.S. EPA Mid-Continent Ecology Division, Duluth, MN, 2 ILSI Health and Environmental Sciences Institute, Washington, D.C. and 3 Department of Environmental Health Sciences, University of South Carolina, Columbia, SC. #2464 2:07 ADVANCES AND OUTLOOKS FOR QSARS IN ECOTOXICOLOGY. S. A. Villalobos 1 , S. E. Belanger 2 and P. Ranslow 3 . 1 Nalco, Naperville, IL, 2 Procter & Gamble, Cincinnati, OH and 3 Consortium for Environmental Risk Management, Hallowell, ME. Abstract # #2465 2:39 FISH EMBRYO AND CELL LINE ASSAYS AS POTENTIAL ALTERNATIVES FOR FISH TOXICITY TESTS. K. Schirmer 1 , K. Tanneberger 1 , M. Knöbel 1,3 , N. Kramer 2 , J. Hermens 2 , S. Scholz 3 , N. Bols 4 , L. Lee 5 and C. Hafner 6 . 1 Eawag, Swiss Federal Institute of Aquatic Science and Technology, Dübendorf, Switzerland, 2 Institute of Risk Assessment Sciences, University of Utrecht, Utrecht, Netherlands, 3 UFZ, Helholtz Centre for Environmental Research, Leipzig, Germany, 4 University of Waterloo, Waterloo, ON, Canada, 5 Wilfrid Laurier University, Waterloo, ON, Canada and 6 Hydrotox GmbH, Freiburg, Germany. Sponsor: M. Embry. #2466 3:11 CRITICAL EVALUATION OF ANIMAL ALTERNATIVE TESTS FOR THE IDENTIFICATION OF ENDOCRINE ACTIVE SUBSTANCES. F. Busquet 1 , S. Belanger 2 , R. Davi 3 , B. Demeneix 4 , J. Denny 5 , M. Embry 6 , M. Léonard 7 , M. McMaster 8 , L. Ortego 9 , P. Renner 10 , D. Villeneuve 5 and S. Scholz 10 . 1 JRC, IHCP, ECVAM, European Commission, Ispra, Italy, 2 Procter & Gamble, Cincinnati, OH, 3 ExxonMobil, Annandale, NJ, 4 Muséum National d’Histoire Naturelle, CNRS, Paris, France, 5 U.S. EPA, Duluth, MN, 6 ILSI HESI, Washington, D.C., 7 L’Oréal Recherche Avancée, Aulnay sous Bois, France, 8 Environment Canada, Burlington, ON, Canada, 9 Bayer CropScience, Research Triangle Park, NC and 10 UFZ, Leipzig, Germany. #2467 3:43 THE OECD FISH TESTING FRAMEWORK PROJECT. L. Touart 1 , G. Ankley 2 , M. Embry 3 , A. Gourmelon 4 , T. Iguchi 5 , G. Maack 6 , P. Matthiessen 7 , J. Wheeler 8 and C. Willett 9 . 1 OCSPP/ Office of Science Coordination and Policy, U.S. EPA, Washington, D.C., 2 Office of Research and Development, NHEERL, Mid-Continent Ecology Division, U.S. EPA, Duluth, MN, 3 ILSI Health and Environmental Sciences Institute, Washington, D.C., 4 Organisation for Economic Cooperation and Development (OECD), Paris, France, 5 National Institute for Basic Biology (NIBB), Okazaki, Japan, 6 Umweltbundesamt (UBA), Dessau, Germany, 7 Consultant, Ulverston, United Kingdom, 8 Syngenta, Bracknell, United Kingdom and 9 PETA, Norfolk, VA. Wednesday Afternoon, March 9 1:30 PM to 4:15 PM Room 204 Workshop Session: De-Risking the Potential for Cardiovascular Toxicity of Type-2 Diabetic Drugs: Preclinical and Clinical Strategies Chairperson(s): Alan Bass, Merck & Co., Kenilworth, NJ, and Peter Hoffmann, Novartis, East Hanover, NJ. Sponsor: Drug Discovery Toxicology Specialty Section Endorsed by: Cardiovascular Toxicology Specialty Section Discovery of effective therapies for the treatment of Type 2 Diabetes (T2D) remains an important and critical unmet medical need for society. As with the development of most new pharmaceuticals, the risk of failure of a compound to achieve marketing authorization remains high. As a result, the pharmaceutical industry has placed a strong commitment in implementing strategies that de-risk the chance of failure when a compound is selected for development. This commitment is reflected in the increasing Wednesday Poster Sessions Regional Interest Session Roundtable Sessions Symposium Sessions Thematic Sessions Workshop Sessions 333
Page 1 and 2:
50 th Anniversary Annual Meeting &
Page 3 and 4:
Scientific Program Overview A page
Page 5 and 6:
9:00 AM-12:30 PM POSTER SESSionS
Page 7 and 8:
March 6-10, 2011 Walter E. Washingt
Page 9 and 10:
Celebration Activities Historical H
Page 11 and 12:
of the Society Regional Chapter Yea
Page 13 and 14:
SOT Presidents 1961-2011 1966 1967
Page 15 and 16:
The SOT Council Thanks and Recogniz
Page 17 and 18:
of the Past 50 Years 2003 Michael D
Page 19 and 20:
Thank You to the following individu
Page 21 and 22:
SOT Celebration Event Floor Plan Ba
Page 23 and 24:
50 th Anniversary Annual Meeting an
Page 25 and 26:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 27 and 28:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 29 and 30:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 31 and 32:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 33 and 34:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 35 and 36:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 37 and 38:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 39 and 40:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 41 and 42:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 43 and 44:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 45 and 46:
Toxicological Sciences The Official
Page 47 and 48:
Society of Toxicology 2011 Walter E
Page 49 and 50:
Society of Toxicology 2011 Washingt
Page 51 and 52:
Society of Toxicology 2011 Map of W
Page 53 and 54:
2011 SOT 50 th Anniversary Featured
Page 55 and 56:
Society of Toxicology 2011 Washingt
Page 57 and 58:
Society of Toxicology 2011 ToxExpo
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Society of Toxicology 2011 Exhibito
Page 65 and 66:
Creating a Safer and Healthier Worl
Page 67 and 68:
Society of Toxicology 2011 General
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
SOT Job Bank YOUR RECRUITMENT AND E
Page 83 and 84:
Society of Toxicology 2011 Career R
Page 85 and 86:
Society of Toxicology 2011 SOT 2011
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Society of Toxicology 2011 2011 Awa
Page 95 and 96:
Endowment Awardees for SOT’s 50 t
Page 97 and 98:
Society of Toxicology 2011 SOT Endo
Page 99 and 100:
Society of Toxicology 2011 Recognit
Page 101 and 102:
Society of Toxicology 2011 Recognit
Page 103 and 104:
Society of Toxicology 2011 RC, SIG,
Page 105 and 106:
Society of Toxicology 2011 Student
Page 107 and 108:
Society of Toxicology 2011 Outreach
Page 109 and 110:
Society of Toxicology 2011 Satellit
Page 111 and 112:
Society of Toxicology 2011 Continui
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Society of Toxicology 2011 Scientif
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Society of Toxicology 2011 Poster S
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Society of Toxicology 2011 Program
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304: Society of Toxicology 2011 Program
Page 353: Society of Toxicology 2011 Program
Page 381 and 382: Society of Toxicology 2011 Author I
Page 405 and 406:
Society of Toxicology 2011 Author I
Page 407 and 408:
Society of Toxicology 2011 Author I
Page 409 and 410:
Society of Toxicology 2011 Abstract
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Society of Toxicology 2011 2010-201
Page 427 and 428:
Society of Toxicology 2011 Elected
Page 429 and 430:
Society of Toxicology 2011 Elected
Page 431 and 432:
Society of Toxicology 2011 Regional
Page 433 and 434:
Society of Toxicology 2011 Specialt
Page 435 and 436:
Society of Toxicology 2011 Specialt
Page 437 and 438:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 439 and 440:
Society of Toxicology 2011 Endowmen
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Society of Toxicology 2011 SOT Affi
Page 449 and 450:
Society of Toxicology 2011 Notes up
Page 451 and 452:
Society of Toxicology 2011 Notes up
Page 453 and 454:
Society of Toxicology 2011 Headquar
Page 455 and 456:
QUICK REFERENCE Visit www.mwata.com
show all

Program - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?